Cargando…

Matrine Activates PTEN to Induce Growth Inhibition and Apoptosis in (V600E)BRAF Harboring Melanoma Cells

Here, we report a natural chemical Matrine, which exhibits anti-melanoma potential with its PTEN activation mechanism. Matrine effectively inhibited proliferation of several carcinoma cell lines, including melanoma (V600E)BRAF harboring M21 cells. Flow cytometry analysis showed Matrine induced G(0)/...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jin, Hui, Sun, Yu, Wang, Shuiying, Cheng, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Molecular Diversity Preservation International (MDPI) 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759898/ https://www.ncbi.nlm.nih.gov/pubmed/23912239 http://dx.doi.org/10.3390/ijms140816040

Ejemplares similares

BRaf(V600E) cooperates with Pten silencing to elicit metastatic melanoma
por: Dankort, David, et al.
Publicado: (2009)

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells
por: Fedorenko, Inna V., et al.
Publicado: (2015)

Genetic inactivation or pharmacological inhibition of Pdk1 delays development and inhibits metastasis of Braf(V600E)::Pten−/− melanoma
por: Scortegagna, Marzia, et al.
Publicado: (2013)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations
por: Giunta, Emilio Francesco, et al.
Publicado: (2020)

Immunohistochemical BRAF V600E Expression and Intratumor BRAF V600E Heterogeneity in Acral Melanoma: Implication in Melanoma-Specific Survival
por: Ito, Takamichi, et al.
Publicado: (2020)

Bioenergetic modulation with dichloroacetate reduces the growth of melanoma cells and potentiates their response to BRAF(V600E) inhibition
por: Abildgaard, Cecilie, et al.
Publicado: (2014)

48218 Preclinical modeling of BRAF(V600E)/PTEN-/- melanoma leptomeningeal disease (LMD) to assess intrathecal checkpoint blockade
por: Guerrieri, Renato A., et al.
Publicado: (2021)

The role of BRAF V600 mutation in melanoma
por: Ascierto, Paolo A, et al.
Publicado: (2012)

Multifocal BRAF(V600E)-Mutated Melanoma in situ on the Foot
por: Iwama, Eimei, et al.
Publicado: (2015)

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated
por: Al Hashmi, Muna, et al.
Publicado: (2020)

Acquired resistance to BRAF inhibition in BRAF(V600E) mutant gliomas
por: Yao, Tsun-Wen, et al.
Publicado: (2016)

AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
por: Hu, W, et al.
Publicado: (2013)

Utility of BRAF VE1 Immunohistochemistry as a Screening Tool for Colorectal Cancer Harboring BRAF V600E Mutation
por: Kwon, Jeong-Hwa, et al.
Publicado: (2018)

BRAF V600E Inhibitor (Vemurafenib) for BRAF V600E Mutated Low Grade Gliomas
por: Del Bufalo, Francesca, et al.
Publicado: (2018)

BRAF Mutation (V600E) Prevalence in Mexican Patients Diagnosed with Melanoma
por: Zepeda-Lopez, Priscilla Denise, et al.
Publicado: (2016)

Desmoplastic infantile astrocytoma with atypical phenotype, PTEN homozygous deletion and BRAF V600E mutation
por: Megías, Javier, et al.
Publicado: (2022)

Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation()()
por: Caruso, Maria, et al.
Publicado: (2014)

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation
por: Čepulytė, Rūta, et al.
Publicado: (2020)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

BRAF(V600E )mutations in malignant melanoma are associated with increased expressions of BAALC
por: Schrama, David, et al.
Publicado: (2008)

Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
por: Sponghini, Andrea P, et al.
Publicado: (2015)

Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells
por: Sapkota, Bishu, et al.
Publicado: (2013)

Frequency of BRAF V600E Mutation in the Mexican Population of Patients With Metastatic Melanoma
por: Ruiz-Garcia, Erika, et al.
Publicado: (2017)

Targeting Notch enhances the efficacy of ERK inhibitors in BRAF-V600E melanoma
por: Krepler, Clemens, et al.
Publicado: (2016)

BRAF V600E mutational load as a prognosis biomarker in malignant melanoma
por: Sevilla, Arrate, et al.
Publicado: (2020)

Targeted Therapy for Melanomas Without BRAF V600 Mutations
por: Menzer, Christian, et al.
Publicado: (2022)

BRAF(non-V600E) more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAF(V600E) but without a survival advantage
por: Wang, Wei, et al.
Publicado: (2021)

Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf(V600E) Melanoma
por: Signetti, Laurie, et al.
Publicado: (2020)

Overcoming resistance to BRAF(V600E) inhibition in melanoma by deciphering and targeting personalized protein network alterations
por: Vasudevan, S., et al.
Publicado: (2021)

Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma
por: Tahiri, Andliena, et al.
Publicado: (2013)

Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation
por: Fernandes, Gustavo S., et al.
Publicado: (2018)

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation
por: Seo, Takuji, et al.
Publicado: (2020)

Overwhelming response to Dabrafenib in a patient with double BRAF mutation (V600E; V600M) metastatic malignant melanoma
por: Ponti, Giovanni, et al.
Publicado: (2012)

Papillary thyroid cancer organoids harboring BRAF(V600E) mutation reveal potentially beneficial effects of BRAF inhibitor-based combination therapies
por: Chen, Dong, et al.
Publicado: (2023)

LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION
por: Nobre, Liana, et al.
Publicado: (2020)

BRAF, MEK and EGFR inhibition as treatment strategies in BRAF V600E metastatic colorectal cancer
por: Ros, Javier, et al.
Publicado: (2021)

Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma
por: Nelson, Blessie Elizabeth, et al.
Publicado: (2023)

BRAF V600E and Pten deletion in mice produces a histiocytic disorder with features of Langerhans cell histiocytosis
por: Nelson, David S., et al.
Publicado: (2019)

Selective inhibition of V600E-mutant BRAF gene induces apoptosis in thyroid carcinoma cell lines
por: Park, Kyoung Sik, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mgje4hafortpcoo1bd9ft2a1v6